AI reads myeloma cells to predict genetic risks

NCT ID NCT07410403

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Fuling Zhou Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study uses artificial intelligence to analyze the shape of individual myeloma cells from bone marrow samples. The goal is to predict genetic abnormalities (called FISH abnormalities) without relying on subjective human review. If it works, this AI method could make genetic testing faster, cheaper, and more accurate for multiple myeloma patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a faster, cheaper, and more accurate way to predict genetic risks in multiple myeloma patients.

What could go wrong

This is a very small early study with only 10 participants, so results may not apply to all patients. The AI method needs much more testing before it can be used in clinics.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 410071, China